harringtonine/лейкоз

Ссылка сохраняется в буфер обмена

СтатьиКлинические испытанияПатенты

Выберите тип сортировки

Страница 1 от 69 полученные результаты

Inhibition of harringtonine-induced apoptosis by tetradecanoylphorbol acetate in human leukemia HL-60 cells.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE To study the changes of the apoptosis induced by camptothecin (Cam) or harringtonine (Har) in human leukemia HL-60 cells after the cells were preincubated with tetradecanoylphorbol acetate (TA). METHODS Chromatin condensation observation, flow cytometry, DNA agarose gel electrophoresis,

[In vitro effect of bortezomib alone or in combination with harringtonine or arsenic trioxide on proliferation and apoptosis of multidrug resistant leukemia cells].

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE To investigate the effect of bortezomib alone or combined with harringtonine (HT) or arsenic trioxide (As2O3) on the proliferation capacity and apoptosis of HL-60/ADM cell line and fresh cells from refractory/relapse acute leukemia patients. METHODS HL-60/ADM cells or refractory/relapse

[Growth inhibition of human myeloid leukemia cells in vitro by harringtonine].

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Harringtonine was discovered as an anticancer agent in China. It has been shown to be effective against myeloid leukemia. In this report, we have demonstrated that harringtonine inhibited the growth of human myeloid leukemia cells in vitro at low concentrations. Together with the clinical data in

Small-dose Harringtonine induces complete remission in patients with acute promyelocytic leukemia.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Small-dose Harringtonine (1-3 mg infused during 4-5 hr) was used as a single agent to treat 10 patients with acute promyelocytic leukemia. Every patient received one to three courses, each lasting 13-81 days (mean 33 days). The interval between courses (i.e., interruptions) was 5-11 days. During

Effects of harringtonine in combination with acivicin, adriamycin, L-asparaginase, cytosine arabinoside, dexamethasone, fluorouracil or methotrexate on human acute myelogenous leukemia cell line KG-1.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Harringtonine (HT) is a new antitumor agent reported to be active in patients with leukemia and lymphoma. The interaction of HT with various antitumor agents was studied in vitro using a human acute myelogenous leukemia cell line KG-1. For the analysis of the drug - drug interaction at the cellular

Potentiation of harringtonine cytotoxicity by calcium antagonist diltiazem and biscoclaurine alkaloid cepharanthine in adriamycin-resistant P388 murine leukemia and K562 human leukemia cells.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Harringtonine showed cross resistance in adriamycin-resistant murine leukemia P388 (P388/ADM) and human leukemia K562 (K562/ADM) cells. The relative resistance of the P388/ADM and K562/ADM cells to harringtonine was about 7 and 40, respectively. Calcium influx blockers, diltiazem and the

HPLC analysis of harringtonine and homoharringtonine in the needles of Cephalotaxus griffithii alkaloid fraction and cytotoxic activity on chronic myelogenous leukaemia K562 cell.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Harringtonine (HT) and homoharringtonine (HHT) are Cephalotaxus alkaloids with considerable antileukaemic activity. The objectives of this research were to (1) determine the content of HT and HHT present in Cephalotaxus griffithii needles alkaloid fraction (CGAF) and (2) compare the

Influence of harringtonine on human leukemia cell differentiation.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

The influence of low doses of harringtonine (Ht) on differentiation of blood cells from acute myeloblastic (AML) and lymphoblastic leukemia (ALL) patients diagnosed according to FAB classification was tested. Out of five cases of ALL only in one case differentiation into mature lymphocytes appeared.

Treatment of acute leukemia with rifampin and low dose harringtonine. Analysis of 14 cases.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

We evaluate the efficacy of rifampin combined with low dose harringtonine in acute leukemia (Group A, acute lymphocytic leukemia (ALL) 6 cases and acute non-lymphocytic leukemia (ANLL) 8 cases) in comparison with the patients treated with low dose harringtonine only (Group B, 8 ALL, and 5 ANLL). The

Long survival in an elderly patient with acute myeloid leukaemia after treatment with harringtonine.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

A remission was achieved in a 73-year-old woman with acute myeloid leukaemia after treatment with harringtonine. The remission lasted 3 1/2 years and she remained alive at the four-year follow-up.

[Enhancement of antitumor activity of harringtonine in human leukemia-60 cells in vitro by verapamil].

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

The effect of harringtonine (Har) alone and in combination with verapamil (Ver) on the proliferation of human leukemia-60 (HL-60) cells in vitro were studied. IC50 of Har alone to the cells was about 49 ng.ml-1 which was reduced to its 1/3.3 and 1/4.5 when used with Ver 1 and 2 micrograms.ml-1,

Effects of anti-leukemia drug Harringtonine on the levels of centromere proteins and gene expression of CenpB in L1210 cells.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

In this study, we investigated the effects of the anti-leukemia drug Harringtonine (HT) on the levels of centromere proteins and gene expression of centromere protein CenpB in L1210 cells. The intensity of centromere fluorescence, shown by indirect immunofluorescence staining, decreased with HT

Enhancing effect of β-elemene emulsion on chemotherapy with harringtonine, aclacinomycin, and Ara-c in treatment of refractory/relapsed acute myeloid leukemia.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Objective : This study is to determine the curative effect of β-elemene emulsion on chemotherapy in the treatment of refractory/relapsed acute myeloid leukemia (AML). Methods : In the β-elemene emulsion plus HAA chemotherapy (harringtonine, aclacinomycin, Ara-c group) group, 120 cases received

Sodium-Periodate-Mediated Harringtonine Derivatives and Their Antiproliferative Activity against HL-60 Acute Leukemia Cells.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

Harringtonine (HT) is a naturally occurring alkaloid isolated from the plant genus Cephalotaxus. It possesses antileukemic activity and has been clinically utilized for the treatment of acute leukemia and lymphoma. Sodium periodate (NaIO4) was reacted with HT to produce five HT derivatives including

Reduction of doxorubicin resistance by tetrandrine and dauricine in harringtonine-resistant human leukemia (HL60) cells.

Только зарегистрированные пользователи могут переводить статьи

Войти Зарегистрироваться

OBJECTIVE To study whether tetrandrine (Tet) and dauricine (Dau) can reduce doxorubicin (Dox) resistance in the harringtonine (Har)-resistant human leukemia cells. METHODS The drug cytotoxities were determined by counting cell numbers and colony formation. Cell cycle phases were assayed by flow

Присоединяйтесь к нашей
странице facebook

Herbal & Natural Medicine

Самая полная база данных о лекарственных травах, подтвержденная наукой

Работает на 55 языках
Травяные лекарства, подтвержденные наукой
Распознавание трав по изображению
Интерактивная карта GPS - отметьте травы на месте (скоро)
Прочтите научные публикации, связанные с вашим поиском
Ищите лекарственные травы по их действию
Организуйте свои интересы и будьте в курсе новостей исследований, клинических испытаний и патентов

Введите симптом или заболевание и прочтите о травах, которые могут помочь, введите лекарство и узнайте о болезнях и симптомах, против которых оно применяется.
* Вся информация основана на опубликованных научных исследованиях.